The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes.
 
Jennifer King
No Relationships to Disclose
 
Rebecca Hassoun
No Relationships to Disclose
 
Sandra K. Althouse
No Relationships to Disclose
 
Christopher A. Fausel
Leadership - Hoosier Cancer Research Network
Honoraria - American Health Resources; ASiM; Medscape; North American Center for Continuing Medical Education; Pharmacy Times; Postgraduate Health Education; Specialty Pharma Education Center
 
Bryan P. Schneider
Honoraria - Lilly; Research to Practice
Research Funding - Epic Sciences; Foundation Medicine; Genentech/Roche; Pfizer
 
Theodore F. Logan
Research Funding - Abbott Laboratories (Inst); Abraxis BioScience (Inst); Acceleron Pharma (Inst); Amgen (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BioVex (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clinigen Group (Inst); Dynavax Technologies (Inst); Eisai (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche (Inst); Synta (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Nabil Adra
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Exelixis; Merck; Sanofi
Research Funding - Exelixis (Inst); Genentech (Inst); Merck (Inst); Natera (Inst)